Incretin hormone mimetics and analogues in diabetes therapeutics

被引：83

作者：

Green, Brian D. ^{[1
]}

Flatt, Peter R. ^{[2
]}

机构：

[1] Queens Univ Belfast, Sch Biol Sci, Belfast BT6 0NJ, Antrim, North Ireland

[2] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2007年 / 21卷 / 04期

关键词：

incretin; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin; type-2; diabetes; glucose homeostasis; exendin;

D O I：

10.1016/j.beem.2007.09.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

引用

页码：497 / 516

页数：20

共 107 条

[91] Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients [J].

Rudovich, NN ;

Rochlitz, HJ ;

Pfeiffer, AFH .

DIABETES, 2004, 53 (09) :2359-2365

[92] Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide [J].

Salhanick, AI ;

Clairmont, KB ;

Buckholz, TM ;

Pellegrino, CM ;

Ha, S ;

Lumb, KJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (18) :4114-4117

[93] The development of beta-cell mass: Recent progress and potential role of GLP-1 [J].

Stoffers, DA .

HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) :811-821

[94] Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells [J].

Trümper, A ;

Trümper, K ;

Hörsch, D .

JOURNAL OF ENDOCRINOLOGY, 2002, 174 (02) :233-246

[95] A role for glucagon-like peptide-1 in the central regulation of feeding [J].

Turton, MD ;

OShea, D ;

Gunn, I ;

Beak, SA ;

Edwards, CMB ;

Meeran, K ;

Choi, SJ ;

Taylor, GM ;

Heath, MM ;

Lambert, PD ;

Wilding, JPH ;

Smith, DM ;

Ghatei, MA ;

Herbert, J ;

Bloom, SR .

NATURE, 1996, 379 (6560) :69-72

[96] ENTERO-INSULAR AXIS [J].

UNGER, RH ;

EISENTRAUT, AM .

ARCHIVES OF INTERNAL MEDICINE, 1969, 123 (03) :261-+

[97] GLUCAGON-LIKE PEPTIDE-1 - A POTENT GLYCOGENIC HORMONE [J].

VALVERDE, I ;

MORALES, M ;

CLEMENTE, F ;

LOPEZDELGADO, MI ;

DELGADO, E ;

PEREA, A ;

VILLANUEVAPENACARRILLO, ML .

FEBS LETTERS, 1994, 349 (02) :313-316

[98] POTENT GLYCOGENIC EFFECT OF GLP-1(7-36)AMIDE IN RAT SKELETAL-MUSCLE [J].

VILLANUEVAPENACARRILLO, ML ;

ALCANTARA, AI ;

CLEMENTE, F ;

DELGADO, E ;

VALVERDE, I .

DIABETOLOGIA, 1994, 37 (11) :1163-1166

[99] Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients [J].

Vilsboll, T ;

Krarup, T ;

Deacon, CF ;

Madsbad, S ;

Holst, JJ .

DIABETES, 2001, 50 (03) :609-613

[100] Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes [J].

Vilsboll, Tina ;

Zdravkovic, Milan ;

Le-Thi, Tu ;

Krarup, Thure ;

Schmitz, Ole ;

Courreges, Jean-Pierre ;

Verhoeven, Robert ;

Buganova, Ingrid ;

Madsbad, Sten .

DIABETES CARE, 2007, 30 (06) :1608-1610

← 2 3 4 5 6 7 8 9 10 11 →